Next Article in Journal
mHealth for Smoking Cessation Programs: A Systematic Review
Previous Article in Journal
Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design
Previous Article in Special Issue
Knowledge, Attitudes and Referral Patterns of Lynch Syndrome: A Survey of Clinicians in Australia
Article Menu

Export Article

Open AccessCase Report
J. Pers. Med. 2014, 4(3), 402-411; doi:10.3390/jpm4030402

Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer

1
Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
2
Rutgers Robert Wood Johnson Medical School, 125 Paterson Street, New Brunswick, NJ 08901, USA
3
Rutgers Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place-MEB 212, New Brunswick, NJ 08903, USA
4
University Radiology Group, 579-A Cranbury Road, East Brunswick, NJ 08816, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 21 March 2014 / Revised: 3 June 2014 / Accepted: 27 June 2014 / Published: 15 July 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice 2013)
View Full-Text   |   Download PDF [834 KB, uploaded 15 July 2014]   |  

Abstract

Classification of pediatric brain tumors with unusual histologic and clinical features may be a diagnostic challenge to the pathologist. We present a case of a 12-year-old girl with a primary intracranial tumor. The tumor classification was not certain initially, and the site of origin and clinical behavior were unusual. Genomic characterization of the tumor using a Clinical Laboratory Improvement Amendment (CLIA)-certified next-generation sequencing assay assisted in the diagnosis and translated into patient benefit, albeit transient. Our case argues that next generation sequencing may play a role in the pathological classification of pediatric brain cancers and guiding targeted therapy, supporting additional studies of genetically targeted therapeutics. View Full-Text
Keywords: glioblastoma; pediatric glioma; metastatic glioma; gene mutation; next generation sequencing; BRAF V600E; vemurafenib; CKDN2A glioblastoma; pediatric glioma; metastatic glioma; gene mutation; next generation sequencing; BRAF V600E; vemurafenib; CKDN2A
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Glod, J.; Song, M.; Sharma, A.; Tyagi, R.; Rhodes, R.H.; Weissmann, D.J.; Roychowdhury, S.; Khan, A.; Kane, M.P.; Hirshfield, K.; Ganesan, S.; DiPaola, R.S.; Rodriguez-Rodriguez, L. Next Generation Sequencing As an Aid to Diagnosis and Treatment of an Unusual Pediatric Brain Cancer. J. Pers. Med. 2014, 4, 402-411.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top